Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Richtig, G; Aigelsreiter, AM; Asslaber, M; Weiland, T; Pichler, M; Eberhard, K; Sygulla, S; Schauer, S; Hoefler, G; Aigelsreiter, A.
Hedgehog pathway proteins SMO and GLI expression as prognostic markers in head and neck squamous cell carcinoma.
Histopathology. 2019; 75(1):118-127 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Aigelsreiter Alena Maria
Aigelsreiter Ariane
Asslaber Martin
Eberhard Katharina
Hoefler Gerald
Pichler Martin
Richtig Georg
Schauer Silvia
Sygulla Stephan
Weiland Thomas
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 2
| |
Abstract:
Because the hedgehog signalling pathway plays a major role in many types of cancer and can nowadays be targeted by specific compounds, we aimed to investigate the role of this pathway in squamous cell carcinoma of the head and neck. Ninety-eight treatment-naive head and neck cancer specimens were immunohistologically stained for SMO, GLI-1, p53 and p16 expression and correlated with clinicopathological factors. Immunoreactivity for SMO and GLI-1 was found in 20 (20.4%) and 52 (53.1%) cases of tumours, respectively. SMO expression correlated with GLI-1 expression (ρ = 0.258, P = 0.010) in univariate and multivariate analysis (P = 0.007, t = 2.81). In univariate analysis, high SMO expression was associated with shorter overall survival (HR = 0.56; 95% CI = 0.32-0.98; P = 0.044) and disease-free survival (HR = 0.53; 95% CI = 0.30-0.95; P = 0.034). In multivariate cox regression analysis SMO expression showed a trend towards an independent predictor for shorter overall survival (HR = 0.57; 95% CI = 0.30-1.05; P = 0.072) and disease-free survival (HR = 0.53; 95% CI = 0.28-1.02; P = 0.056). In head and neck cancer patients with low tumour p16 expression, SMO expression was an independent factor for overall survival (HR = 0.49; 95% CI = 0.24-0.98; P = 0.043) and disease-free survival (HR = 0.45; 95% CI = 0.22-0.96; P = 0.037). Although it needs to be confirmed in larger cohorts, our results suggest that targeting SMO might be a potentially therapeutic option in patients with head and neck cancer. In line, molecular pathological analyses including mutation analysis in the hedgehog pathway might point to additional therapeutic leads. © 2019 The Authors. Histopathology published by John Wiley & Sons Ltd.

Find related publications in this database (Keywords)
head and neck cancer
hedgehog
immunohistochemistry
survival
© Med Uni Graz Impressum